We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

51 hedge funds and large institutions have $13M invested in Cue Biopharma in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

9% more capital invested

Capital invested by funds: $11.9M → $13M (+$1.13M)

9% more funds holding

Funds holding: 47 → 51 (+4)

0.02% more ownership

Funds ownership: 0.77% → 0.78% (+0.02%)

64% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 14

Holders
51
Holders Change
+4
Holders Change %
+8.51%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFM
Boothbay Fund Management
New York
+$478K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$85K
3
GWMR
GC Wealth Management RIA
Massachusetts
+$78.2K
4
Renaissance Technologies
Renaissance Technologies
New York
+$73.2K
5
Squarepoint
Squarepoint
New York
+$67.1K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$116K
2
UBS Group
UBS Group
Switzerland
-$73.1K
3
Northern Trust
Northern Trust
Illinois
-$24.7K
4
SM
Salzhauer Michael
-$10.9K
5
LPL Financial
LPL Financial
California
-$10.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
NA
26
NewEdge Advisors
Louisiana
$14.4K – – –
Wells Fargo
27
Wells Fargo
California
$14.1K – – –
Cambridge Investment Research Advisors
28
Cambridge Investment Research Advisors
Iowa
$14K – – –
PIWA
29
Prevail Innovative Wealth Advisors
Kansas
$13.6K – – –
VF
30
Virtu Financial
New York
$11K -$4.37K -186 -27%
XT
31
XTX Topco
Cayman Islands
$10.6K -$6.08K -259 -35%
Goldman Sachs
32
Goldman Sachs
New York
$10.3K +$23 +1 +0.2%
SWM
33
SeaCrest Wealth Management
New York
$8.58K -$2.35K -100 -23%
TRCT
34
Tower Research Capital (TRC)
New York
$7.28K +$7.93K +338 New
Barclays
35
Barclays
United Kingdom
$4.33K – – –
GG
36
Gleason Group
Kentucky
$4.31K – – –
Simplex Trading
37
Simplex Trading
Illinois
$3K +$3.78K +161 New
NFSG
38
Newbridge Financial Services Group
Florida
$2.16K – – –
GSWM
39
Golden State Wealth Management
California
$1.44K – – –
T
40
Tidemark
California
$1.08K – – –
PWA
41
Physician Wealth Advisors
Utah
$724 – – –
MG
42
Mather Group
Illinois
$719 +$774 +33 New
JP Morgan Chase
43
JP Morgan Chase
New York
$650 -$4.79K -204 -87%
Osaic Holdings
44
Osaic Holdings
Arizona
$512 – – –
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$496 -$23 -1 -4%
MCM
46
MAI Capital Management
Ohio
$252 – – –
SS
47
Sunbelt Securities
Texas
$170 – – –
ASN
48
Advisory Services Network
Georgia
$144 +$164 +7 New
Citigroup
49
Citigroup
New York
$95 +$94 +4 New
AAG
50
Armstrong Advisory Group
Massachusetts
$87 – – –
1
2
3

CUE Hedge Fund Activity: Q3 2025 in Review

51 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2025, worth a combined $13M — up 9.5% from $11.9M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CUE positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 14 trimmed.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $478K. The largest seller was Vanguard Group, cutting an estimated $116K.

  • 51 institutional investors held Cue Biopharma (CUE) as of Q3 2025, up from 47 in Q2 2025.
  • Funds reported $13M of Cue Biopharma stock for Q3 2025, up 9.5% quarter-over-quarter.
  • 8 funds opened new Cue Biopharma positions in Q3 2025 and 4 closed out, a net change of +4 holders.
  • The largest Cue Biopharma buyer in Q3 2025 was Boothbay Fund Management, an estimated $478K added.
  • The largest Cue Biopharma seller in Q3 2025 was Vanguard Group, an estimated $116K sold.

Based on aggregated 13F filings for Q3 2025.